Financial Performance - The company expects a net profit for 2025 to be positive but to decline by over 50% compared to the previous year [3] - Revenue for the reporting period is projected at approximately ¥197,090.55 million, representing an 8% decrease from ¥205,659.71 million in the same period last year [5] - Net profit attributable to shareholders is expected to be around ¥13,605.53 million, a decline of 55% from ¥18,140.71 million year-over-year [5] - The net profit after deducting non-recurring gains and losses is projected to be ¥11,390.44 million, down 58.38% from ¥15,925.62 million in the previous year [5] - The impact of non-recurring gains and losses on net profit is estimated to be approximately ¥22 million, compared to ¥28.65 million in the same period last year [8] Strategic Investments and Business Development - The company has increased strategic investments in the artificial intelligence sector and optimized its personnel structure by recruiting high-end talent in AI algorithm and product development [8] - The company is accelerating the cultivation of new businesses, although these new ventures are expected to contribute low revenue initially [8] Cash Flow and Client Management - Overall cash flow remains stable, but some clients have extended their payment cycles, leading to an increase in the provision for bad debts [7]

证券代码：920719 证券简称：宁新新材 公告编号：2026-001 (一)业绩预告期间 2025 年 1 月 1 日至 2025 年 12 月 31 日。 (二)业绩预告情况 √年度净利润为负值 江西宁新新材料股份有限公司 2025 年年度业绩预告公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、 误导性陈述或者重大遗漏，并对其内容的真实性、准确性和完整性承担个别及连 带法律责任。 特别提示：本公告所载 2025 年年度主要财务数据为初步核算数据，未经会 计师事务所审计，具体数据以公司 2025 年年度报告中披露的数据为准，提请投 资者注意投资风险。 一、本期业绩预告情况 三、风险提示 本次业绩预告为公司财务部门初步测算的结果，尚未经会计师事务所审计， 具体数据以公司 2025 年年度报告中披露的数据为准。 敬请广大投资者谨慎决策，注意投资风险。 江西宁新新材料股份有限公司 董事会 2026 年 1 月 30 日 单位：万元 | 项目 | | 本报告期 | | 上年同期 | 变动比例% | | --- | --- | --- | --- | --- | --- | | 归属于上市 ...

证券代码：000731 证券简称：四川美丰 公告编号：2026-04 三、业绩变动原因说明 （一）主营业务影响。报告期内，公司主营的化肥化工产品所 处行业新增产能释放，下游市场需求增速放缓。产品端：尿素、三 聚氰胺、硝酸铵、LNG 等主要产品市场价格持续下跌；成本端：复 合肥生产用主要原料市场行情总体呈攀升走势，价格中枢整体上移。 公司采取的应对举措：一是深耕市场布局，全力开拓客户资源，推 动部分主营产品销量实现同比增长；二是提升运营效率，全面落实 四川美丰化工股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整， 没有虚假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况：预计净利润为负值 | 项 | 目 | | 本报告期 | | 上年同期 | | | --- | --- | --- | --- | --- | --- | --- | | 归属于上市公司股东的净 利润 | | 亏损：9,800 | 万元–12,900 | 万元 | 盈利：27,173.78 | ...

证券代码：002082 证券简称：万邦德 公告编号：2026-007 万邦德医药控股集团股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、本期业绩预计情况 1、业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日。 二、与会计师事务所沟通情况 本次业绩预告未经会计师事务所审计，公司已就业绩预告有关事项与会计 师事务所进行预先沟通，公司与会计师事务所在业绩预告方面不存在重大分歧。 三、业绩变动原因说明 1、公司受国家药品、医疗器械招标、集采政策持续推进的影响，集采覆 盖区域的进一步扩大，公司相关产品集采后价格下降明显，行业市场竞争加剧， 在第十批国家集采中有产品未能中标，造成公司利润大幅度下降。 2、公司由仿制药向创新药战略发展转型升级，加速创新药全球研发力度， 研发投入加大。 3、公司创新药国际化制剂车间、原料药基地、中非医疗科技园国际化标 准的器械车间投入大，投入使用的固定资产折旧增加，但尚未形成规模效应。 4、报告期内，高分子产品生产厂区整体异地搬迁，影响医疗器械产品的 生产与市场供应。 2 ...

Financial Performance Expectations - The company expects a net profit in the range of -12 million to -8 million RMB for 2025, representing a significant improvement of 92.86% to 95.24% compared to the previous year's net loss of 168.03 million RMB[5] - The net profit after deducting non-recurring gains and losses is projected to be between 5 million and 7.5 million RMB, marking an increase of 119.23% to 128.85% from a loss of 26 million RMB in the previous year[5] - The basic earnings per share are expected to be in the range of -0.015 to -0.010 RMB, compared to -0.21 RMB in the previous year[5] Operational Developments - The company’s subsidiary, Sinochem Dongda (Quanzhou) Co., Ltd., successfully launched a 240,000 tons/year polyether polyol project, contributing to partial profits during the reporting period[4] - The company has implemented refined management practices and strengthened its technical and marketing systems, leading to significant cost reduction and efficiency improvements[4] - The company is undergoing a site restoration project for certain land parcels, which has been publicly tendered, and the total restoration costs have been re-evaluated and accrued[4] Financial Reporting and Risk Awareness - The financial data in this earnings forecast has not been audited by the accounting firm, but preliminary discussions have been held without major discrepancies[3] - The company emphasizes the importance of investor awareness regarding investment risks associated with the preliminary earnings forecast data[6] - The reporting period for the earnings forecast is from January 1, 2025, to December 31, 2025[3] - The company will provide detailed financial data in its 2025 annual report[6]

Financial Performance - The company expects a net profit in the range of -5,000 to -3,000 thousand yuan, representing a year-on-year increase of 97.14% to 98.28% compared to the previous year's net profit of -17,465.34 thousand yuan[5]. - The net profit after deducting non-recurring gains and losses is projected to be between -18,000 and -12,000 thousand yuan, showing a year-on-year increase of 90.75% to 93.83% from -19,452.68 thousand yuan in the same period last year[5]. - The basic earnings per share are expected to be between -0.0099 and -0.0050 yuan, compared to -0.34 yuan in the previous year[5]. Operational Management - The company has implemented lean operational management in its medical sector, enhancing operational efficiency through process optimization and cost control measures[7]. - The company anticipates a significant reduction in goodwill impairment compared to 2024, where the impairment provision was 13,463.26 thousand yuan[8]. Earnings Forecast - The financial data presented is preliminary and has not yet been audited by the accounting firm, but there are no significant discrepancies reported[6]. - The company emphasizes the importance of cautious decision-making for investors due to the preliminary nature of the earnings forecast[9]. - The earnings forecast period is from January 1, 2025, to December 31, 2025[3]. - The company has communicated with the accounting firm regarding significant matters related to the earnings forecast[6]. Incentive Plan - The company did not meet the performance assessment trigger values for the 2023 restricted stock incentive plan for the year 2025, leading to a reversal of previously accrued share-based payment expenses[7].

Financial Projections - The estimated net profit for 2025 is projected to be between 1.1 billion and 1.4 billion CNY, representing a year-on-year change of -19.38% to 2.61%[3] - The estimated net profit after deducting non-recurring gains and losses is expected to be between 870 million and 1.1 billion CNY, with a year-on-year decline of -47.11% to -33.12%[3] - The company’s non-recurring gains and losses for 2025 are estimated to be between 230 million and 300 million CNY, compared to -280 million CNY in the previous year due to the reversal of deferred tax assets[7] Performance Metrics - Mango TV's effective play volume for TV dramas increased by 28.12% year-on-year, maintaining a positive growth trend[5] - The number of effective members for Mango TV reached nearly 75.6 million, with a mobile MAU of 268 million, reflecting a year-on-year growth of 4.88%[6] - The "Big Mango Plan" resulted in the launch of 5,137 micro-short dramas in 2025, representing an increase of over 14 times compared to the previous year[6] Strategic Initiatives - Mango TV was ranked 20th in the "Top 100 Comprehensive Strength of Chinese Internet Enterprises" and is the only state-controlled enterprise in the top twenty[5] - The company is focusing on enhancing quality content and technological innovation, which has increased operational costs and impacted current profits[7] - Mango TV's international expansion plan is progressing smoothly, being selected as a key enterprise for cultural exports in 2025-2026[6] - The company achieved its first annual profit in the IP derivative product development segment, marking a significant turning point[6]

证券代码：002586 证券简称：ST 围海 公告编号：2026-002 浙江省围海建设集团股份有限公司 2、业绩预告情况：预计净利润为正值且属于扭亏为盈情形 （1）以区间数进行业绩预告的 单位：万元 | 项 目 | 本报告期 | | | | 上年同期 | | --- | --- | --- | --- | --- | --- | | 归属于上市公司 | 27,500 | | ～ | 41,000 | -15,108.69 | | 股东的净利润 | 比上年同期增长 | 282.01% | ～ | 371.37% | | | 扣除非经常性损 | 3,300 | | ～ | 4,900 | -16,895.82 | | 益后的净利润 | 比上年同期增长 | 121.31% | ～ | 131.96% | | | 基本每股收益 （元/股） | 0.2403 | | ～ | 0.3583 | 0.1320 | 二、与会计师事务所沟通情况 本次业绩预告相关数据是公司财务部门初步测算的结果，未经注册会计师审计。公司 就本次业绩预告有关事项与年报审计会计师事务所进行了初步沟通，双方不存在分歧。 三、业绩变动原因说明 202 ...

证券代码：300721 证券简称:怡达股份 公告编号：2026-002 一、本期业绩预计情况 （一）业绩预告期间：2025 年 1 月 1 日至 2025 年 12 月 31 日 （二）业绩预告情况： 预计净利润为负值； | 项目 | 本期报告 | | 上年同期 | | | --- | --- | --- | --- | --- | | 归属于上市公司 股东的净利润 | 亏损：10,000 | 万元-12,000 万元 | 盈利：953.31 | 万元 | | 扣除非经常性损 益后的净利润 | 亏损：10,033.06 | 万元 万元-12,033.06 | 盈利：1,137.55 | 万元 | 二、与会计师事务所沟通情况 本期业绩预告相关数据是公司财务部门初步测算结果，未经审计机构审计。 公司就业绩预告有关事项已与会计师事务所进行预沟通，公司与会计师事务所在 本次业绩预告方面不存在分歧。 三、业绩变动原因说明 江苏怡达化学股份有限公司 2025 年度业绩预告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有 虚假记载、误导性陈述或重大遗漏。 2、 本期业绩具体数据将在公司 2025 年度报告中 ...

Financial Projections - The estimated net profit for 2025 is projected to be between RMB 120 million and RMB 160 million, representing a year-on-year increase of 114.53% to 186.05% compared to RMB 55.93 million in the previous year[3] - The estimated net profit after deducting non-recurring gains and losses is projected to be between RMB 112 million and RMB 152 million, reflecting a year-on-year growth of 66.03% to 125.32% compared to RMB 67.46 million in the previous year[3] - The estimated impact of non-recurring gains and losses on the net profit attributable to shareholders is approximately RMB 8 million, primarily from government subsidies[6] - The performance forecast has not been audited by the accounting firm, and specific financial data will be disclosed in the 2025 annual report[7] Business Performance Drivers - The significant growth in performance is driven by the company's proactive market opportunities, expanded customer channels, and enhanced management efficiency[5] - The company has optimized its product structure and improved market layout, leading to increased revenue and gross profit in its non-sartan and formulation businesses[6] - The company has effectively reduced losses by significantly cutting back on foreign exchange derivative trading[6] Investor Guidance - The company emphasizes the importance of cautious decision-making and awareness of investment risks for investors[7]